



## Recent Research on Human Papillomavirus (HPV) Infection and Vaccination

Guest Editors:

### Dr. Li Shi

Laboratory of Immunogenetics,  
Institute of Medical Biology,  
Chinese Academy of Medical  
Science & Peking Union Medical  
College, Kunming 650118, China

### Prof. Dr. Yufeng Yao

Institute of Medical Biology,  
Chinese Academy of Medical  
Sciences and Peking Union  
Medical College, Kunming  
650118, China

Deadline for manuscript  
submissions:

**31 December 2024**

### Message from the Guest Editors

In recent years, significant progress has been made in cervical cancer prevention, especially in terms of the availability of prophylactic vaccines. However, the HPV vaccine has not yet achieved full coverage, and rates have dropped during the COVID-19 pandemic. It is therefore necessary to strengthen HPV vaccine education, vaccination and early prevention. Meanwhile, exploring the various aspects underlying the mechanism of progression of HPV-associated malignancies, host immune system reactions toward HPV viruses as well as HPV vaccination are important for the development of specific therapeutics and vaccines against viral clinical manifestations.

Research areas: the knowledge and attitudes surrounding prophylactic HPV vaccination; vaccination implementation; effective instruments or interventions to improve public awareness of HPV vaccination; vaccination equity; the impact of the COVID-19 pandemic on HPV vaccination; host factors related to HPV infection, persistent, cervical intraepithelial neoplasia, and cervical cancer; co-infection of HPV with other pathogens; progression of HPV-associated malignancies; HPV and host-virus interaction; novel HPV vaccine development.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)